Vancomycin dosing in children: what is the question?

被引:14
作者
Cole, Theresa S. [1 ]
Riordan, Andrew [1 ]
机构
[1] Alder Hey Childrens NHS Fdn Trust, Dept Infect Dis & Immunol, Liverpool L12 2AP, Merseyside, England
关键词
SUBSEQUENT SERUM CONCENTRATIONS; INFECTIOUS-DISEASES SOCIETY; CONTINUOUS-INFUSION; GUIDELINES; AMERICA;
D O I
10.1136/archdischild-2013-304169
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Vancomycin has been in clinical use for over 60 years, but it is still not clear what dose should be given to children. Effective treatment with vancomycin requires a serum concentration well above the minimum inhibitory concentration (MIC) of the bacteria being treated. This is predicted by the area under the concentration curve (AUC) divided by the MIC being >400 (AUC/MIC). Recent concerns about increasing MIC in staphylococci have lead to recommendations to aim for higher trough vancomycin levels (15-20 mg/L). In current practice, most children do not achieve these trough levels. Modelling and pharmacokinetic studies in children suggest these trough levels may not be necessary if the MIC of the organisms is 1 mg/L or less. Further, large-scale studies are needed to determine the most appropriate dosing of vancomycin in children. While awaiting these, it is time to consider moving to 15 mg/kg 6 h as a standard starting regime for vancomycin. It is also vital to determine the MIC of the organism being treated, as this may give some guidance about suitable trough levels to be aimed for. There is currently little evidence to guide the use of loading doses or continuous vancomycin infusions in children.
引用
收藏
页码:994 / 997
页数:4
相关论文
共 25 条
[1]   Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients [J].
Bourguignon da Silva, Dafne Cardoso ;
Finoti Seixas, Glaucia Toribio ;
de Araujo, Orlei Ribeiro ;
Arduini, Rodrigo Genaro ;
de Moraes Costa Carlesse, Fabianne Altruda ;
Petrilli, Antonio Sergio .
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 16 (04) :361-365
[2]   An Evaluation of Initial Vancomycin Dosing in Infants, Children, and Adolescents [J].
Broome, Laura ;
So, Tsz-Yin .
INTERNATIONAL JOURNAL OF PEDIATRICS, 2011, 2011
[3]  
CANTU TG, 1994, CLIN INFECT DIS, V18, P533
[4]   Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus [J].
Charles, PGP ;
Ward, PB ;
Johnson, PDR ;
Howden, BP ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (03) :448-451
[5]  
Chhim RF, 2013, J PEDIAT INF DIS SOC, V2, P259, DOI 10.1093/jpids/pis083
[6]   Assessment of Vancomycin Dosing and Subsequent Serum Concentrations in Pediatric Patients [J].
Eiland, Lea S. ;
English, Thomas M. ;
Eiland, Edward H., III .
ANNALS OF PHARMACOTHERAPY, 2011, 45 (05) :582-589
[7]   Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review [J].
Elyasi, Sepideh ;
Khalili, Hossein ;
Dashti-Khavidaki, Simin ;
Mohammadpour, Amirhooshang .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (09) :1243-1255
[8]  
European Committee on Antimicrobial Susceptibility Testing, EUCAST MIC DISTR WEB
[9]   Desired Vancomycin Trough Serum Concentration for Treating Invasive Methicillin-resistant Staphylococcal Infections [J].
Frymoyer, Adam ;
Guglielmo, B. Joseph ;
Hersh, Adam L. .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (10) :1077-1079
[10]   Impact of a Hospitalwide Increase in Empiric Pediatric Vancomycin Dosing on Initial Trough Concentrations [J].
Frymoyer, Adam ;
Guglielmo, B. Joseph ;
Wilson, Stephen D. ;
Scarpace, Sarah B. ;
Benet, Leslie Z. ;
Hersh, Adam L. .
PHARMACOTHERAPY, 2011, 31 (09) :871-876